Gemphire Therapeutics (GEMP): Gearing up for three Phase 2 read outs in 2017 - RBC

September 15, 2016 7:42 AM EDT
Get Alerts GEMP Hot Sheet
Price: $8.57 -2.06%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade GEMP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

RBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Gemphire Therapeutics (NASDAQ: GEMP) along with the price target of $25.00.

Over the next few months, three planned Phase 2 studies will start and continue to enroll patients with HoFH, HeFH/ASCVD and SHTG. As Phase 2 data gets top-lined in 2017, the market will be set up for important inflection points.

For an analyst ratings summary and ratings history on Gemphire Therapeutics click here. For more ratings news on Gemphire Therapeutics click here.

Shares of Gemphire Therapeutics closed at $11.21 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

RBC Capital

Add Your Comment